Memantina Aurobindo (Memantine Hydrochloride)

Memantine acts as a non‑competitive antagonist at NMDA receptors, reducing excessive calcium influx caused by glutamate over‑activation. This limits excitotoxic neuronal injury, which is a key contributor to the cognitive decline seen in Alzheimer’s disease.

The dosage of Memantina Aurobindo is determined by the prescribing physician based on the patient’s clinical condition, renal function, and response to therapy. The prescriber will set the appropriate dose and titration schedule.

Safety data for memantine in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA‑receptor antagonist class, whereas cholinesterase inhibitors such as donepezil act by increasing acetylcholine levels. Memantine is typically used in moderate to severe stages, often in combination with a cholinesterase inhibitor, offering a complementary mechanism of neuroprotection.

Store Memantina Aurobindo at room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Memantina Aurobindo is taken orally, usually with or without food, as directed by the prescribing physician. The tablets should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious adverse events, although rare, include seizures, severe hypotension, cardiac arrhythmias, hepatic dysfunction, and severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for any of these symptoms and seek immediate medical attention if they occur.

Memantina Aurobindo is contraindicated in patients with known hypersensitivity to memantine or any of its excipients. Caution is advised in individuals with severe renal impairment, uncontrolled hypertension, or a history of seizures, and it should be avoided in combination with other NMDA antagonists.